Global Statistics Representing Hepatitis B Therapeutics Market Scenario
According to the World Health Organization, (WHO) approximately 257 million people are living with hepatitis B virus infection globally. Growing incidence of hepatitis B is driving the growth of the hepatitis B therapeutics market. Furthermore, hepatitis B is potentially life threatening liver infection caused by hepatitis B virus. It is a global health problem and can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer. Additionally, in 2015, around 887000 people died due to hepatitis B across the globe. Hepatitis B vaccine is 95% effective in preventing infection, chronic infection, chronic liver diseases and liver cancer. Furthermore, infection can be spread during medical, surgical and dental procedures, through tattooing, or using razors is supporting the growth of hepatitis B therapeutics market.
The global Hepatitis B therapeutics market was valued around USD 3,500 million in 2017 and expected to grow at the CAGR of 4.6% in the forecast period.
The Hepatitis B therapeutics market is segmented by therapy, product type and distribution channel.
On the basis of therapy, the market is segmented into chemo therapy, immunosuppressant therapy and nucleoside analogue. Nucleoside analogue is expected to dominate the market in the forecast period.
Based on product type, the market is segmented into Hepatitis B vaccine and anti-viral drugs. Hepatitis B vaccine is expected to grow at a significant rate owing to high prevalence of antiviral drug resistance.
On the basis of distribution channel, the Hepatitis B therapeutics market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
Geographically, the global Hepatitis B therapeutics market is segmented into North America, Europe, Asia Pacific, and the Latin America and the Middle East & Africa (LAMEA).
North America is expected to have a potential growth in the Hepatitis B therapeutic market during the forecast period 2019-2026. According to the Centers for Diseases Control and Prevention (CDC), in 2016, approximately 3,218 cases of acute Hepatitis B were reported in the U. S. Increasing prevalence of hepatitis B is driving the growth of the market. Hepatitis B therapeutics market is growing in the U.S. via sexually transmitted diseases.
Europe is expected to be the second leading region in the global hepatitis B therapeutics market. Increasing prevalence of hepatitis B owing to less availability of antibiotics in the market and effectiveness of antivirals against Hepatitis B infections is propelling the growth of the market. Furthermore, medications and treatment of Hepatitis B are highly expensive thus, increasing per capita income is driving the growth of the market.
Asia Pacific (APAC) is expected to be the fastest growing region during the forecast period 2019–2025. According to the World Health Organization, approximately 40 million people suffered from hepatitis B infection in India. Increasing prevalence of hepatitis B in Asian countries is propelling the growth of the hepatitis B therapeutics market. Furthermore, increasing incidence of lymph proliferative disease, acquired immuno deficiency syndrome (AIDS), and immunosuppressant drugs and hemodialysis patients prone to develop an infection with Hepatitis-B Virus in this region.
Latin America is expected to attain steady growth due to less penetration of hepatitis B therapeutics market. However, increasing awareness about hepatitis B is growing in the region which positively impacting the growth of the market.
Major players operating in the global hepatitis B therapeutics market include Johnson & Johnson, GlaxoSmithKline plc, Abivax SA, Novira Therapeutics, F. Hoffmann- La Roche and Bristol-Myers Squibb.
In 2015, Mylan launched lamivudine tablets for treatment of Epivir-HBV.
In 2018, GlaxoSmithKline plc. launched ENGERIX-B for hepatitis B vaccine recombinant.
Hepatitis B Therapeutics Market Segmentation
By product type
By distribution channel
Why buy this report right now?